24.05.2024  21:45:02 Изменение -0.550 Объем сделки Бид22:00:01 Предложение22:00:01 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
36.850EUR -1.47% 590
Оборот: 22,021
-Величина цены спроса: - -Величина цены предложения: - 2.01 млрдEUR 2.36% 32.16

Описание деятельности

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Правление & Наблюдательный совет

Исполнительный директор
Dr. Hans-Georg Feldmeier
Правление
Dr. Andreas Eberhorn, Christof Dreibholz
Наблюдательный совет
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Данные компании

Имя: Dermapharm Holding SE
Адрес: Lil-Dagover-Ring 7,D-82031 Grünwald
Телефон: +49-89-64186-0
Факс: +49-89-64186-130
E-mail: -
Интернет: ir.dermapharm.de/index.php
Индустрия: Healthcare
Сектор: Pharmaceutical Industry
Подсектор: Pharmaceuticals
Конец финансового года: 31.12
Акции в свободном обращении: -
Дата IPO: 09.02.2018

Связи с инвесторами

Имя: Britta Hamberger
IR телефон: +49-89-64186-233
IR-факс: +49-89-64186-165
IR e-mail: ir@dermapharm.com

Календарь компании

CW 23 | 06.06.2024 Ex-Dividend
CW 23 | 07.06.2024 Record Date
CW 24 | 10.06.2024 Dividend Payment
CW 26 | 27.06.2024 General Shareholder Meeting
CW 35 | 27.08.2024 Interim Report 2nd Quarter/6 Months
 

Основные акционеры

Themis Beteiligungs-AG
 
68.50%
free float
 
31.50%